NasdaqGS:KRYSBiotechs
Krystal Biotech (KRYS) Net Margin Expansion Tests Bullish Long Term Profitability Narratives
Krystal Biotech (KRYS) closed FY 2025 with Q4 revenue of US$107.1 million and basic EPS of US$1.77, rounding out a year where trailing twelve month revenue reached US$389.1 million and EPS came in at US$7.08, alongside reported earnings growth of 129.7% year over year. Over the past six quarters in the dataset, revenue has moved from US$83.8 million in Q3 2024 to US$107.1 million in Q4 2025. Quarterly basic EPS tracked from US$0.95 to US$2.74 and then US$1.77, setting the backdrop for a...